[{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Social Capital Suvretta Holdings Corp. III","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Social Capital Suvretta Holdings Corp. III","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Social Capital Suvretta Holdings Corp. III"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by ProKidney

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : ProKidney will use the proceeds for its drug development, rilparencel (also known as REACT), an autologous cellular therapy evaluated to potentially preserve kidney function in diabetic patients.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 06, 2024

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          02

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : ProKidney will use the proceeds for its drug development, rilparencel (also known as REACT), an autologous cellular therapy evaluated to potentially preserve kidney function in diabetic patients.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 06, 2024

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : $125.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT (rilparencel), a renal autologous homologous cell admixture, made from expanded autologous SRCs, is currently in a late-stage trial for Diabetic Kidney Disease.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 17, 2024

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : $140.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT (rilparencel), an autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 09, 2024

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT, a renal autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject’s kidney biopsy. REACT is currently in a Phase 3 development program for Diabetic Kidney Disease.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 13, 2023

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT, a renal autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject’s kidney biopsy. REACT is currently in a Phase 3 development program for Diabetic Kidney Disease.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 01, 2023

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential not only to slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney fun...

                          Product Name : REACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 04, 2022

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney functio...

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 14, 2022

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The primary objective of this study is to assess the safety and efficacy of up to two REACT (Renal Autologous Cell Therapy) injections delivered into biopsied and non-biopsied contralateral kidneys using a minimally invasive percutaneous approach.

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 06, 2022

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : REACT is an autologous cell therapy produced from a patient’s own kidney cells that is comprised of a proprietary mixture of progenitor cells that have been selected and cultured so they can be placed back into the patient’s kidney to restore the nat...

                          Product Name : ReACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Rilparencel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank